AstraZeneca gets FDA orphan drug designation for Zactima

SarahTurner

LONDON (MarketWatch) -- British pharmaceutical AstraZecenca
AZN, +3.39%AZN, +3.98%
said Monday that the U.S. Food & Drug Adminstration has granted its Zactima treatment orphan drug designation for the investigation of rare forms of thyroid cancer. AstraZeneca said that ZD6474 is currently being developed in a Phase II clinical trial in medullary thyroid cancer, while Phase III clinical trials in advanced non-small cell lung cancer are scheduled to start in the next few months. AstraZeneca has also applied for Orphan Drug designation for ZD6474 in medullary thyroid cancer in Europe.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.